Keywords
Pulmonary hypertension
Sildenafil therapy
Submitted : 2024-04-17
Accepted : 2024-05-02
Published : 2024-05-17
Abstract
Objective: To analyze the improvement of mean pulmonary arterial pressure and oxygenation index as well as the therapeutic effect of sildenafil treatment in patients with congenital heart disease and pulmonary arterial hypertension. Methods: A total of 104 patients with congenital heart disease and pulmonary arterial hypertension were recruited from February 2023 to January 2024 and grouped into study and control groups using a randomized numerical table, with 52 patients in each group. The study group received sildenafil treatment, while the control group received conventional treatment. The therapeutic effects of both groups were analyzed and compared. Results: The study group had an average pulmonary arterial pressure of 26.23 ± 2.16 mmHg, an oxygenation index of 241.63 ± 4.86, and a total effective treatment rate of 98.08%, which was significantly better than the control group (P < 0.05). Conclusion: By implementing sildenafil treatment for patients with congenital heart disease and pulmonary hypertension, the mean pulmonary artery pressure and oxygenation index of the patients improved significantly, and the effective rate of treatment increased significantly.
References
Yang S, Huang G, Liang X, et al., 2024, Clinical Study of Digoxin Combined with Milrinone in the Treatment of Children with Congenital Heart Disease Combined with Heart Failure. Great Physician, 9(3): 37–40.
Yuan Xin, Zheng Y, 2023, Application Effect of Etomidate in Pediatric Congenital Heart Disease Interventional Therapy. Journal of Women’s and Children’s Health, 2(12): 89–91.
Zhang M, Li Y, Wang X, et al., 2023, A Case Report of Travoprostenil for the Treatment of Combined Congenital Heart Disease in Pregnancy with Severe Pulmonary Hypertension. Modern Obstetrics and Gynecology Progress, 32(2): 159.
Zhong S, Huang K, Wei B, et al., 2022, Clinical Study of Targeted Drugs Combined with Surgery in the Treatment of Congenital Heart Disease Combined with Severe Pulmonary Hypertension. Minimally Invasive Medicine, 17(5): 593–596.
Zhou L, Xu Y, Hong D, et al., 2022, Therapeutic Effects of Targeted Drugs on Pulmonary Vascular Reactivity in Children with Congenital Heart Disease Combined with Moderate-to-Severe Pulmonary Hypertension. Journal of Practical Medicine, 38(11): 1395–1399.
Lu G, Lan Z, Wei Q, et al., 2023, Progress of Bosentan Combined with Sildenafil in Patients with Congenital Heart Disease Combined with Pulmonary Hypertension. Chinese Contemporary Medicine, 30(3): 53–56.
Xu Z, Zhang H, Li Q, et al., 2022, Preliminary Study of Compound Clinical Deterioration Events of Pulmonary Hypertension Associated with Congenital Heart Disease. Chinese Journal of Cardiovascular Disease, 50(3): 282–288.
Li J, Zhen X, Zhang J, et al., 2022, Application of Bosentan in the Treatment of Postoperative Pulmonary Hypertension After Congenital Heart Disease and Its Mechanism of Influence on Serum ET-1 and VEGF Levels. Sichuan Journal of Physiological Sciences, 44(9): 1553–1555.
Shi Y, Lei R, Hu B, et al., 2023, Comparison of the Effects of Sildenafil Citrate Tablets and Milrinone Combined with Mechanical Ventilation in Neonates with Persistent Pulmonary Hypertension. Henan Medical Research, 32(11): 2063–2066.